Lihan Zhou

Lihan co-founded and serves as CEO of MiRXES, a Singapore headquartered, RNA centric biotechnology company with the mission to improve and save lives through early, actionable, and accessible cancer early detection tests. Lihan oversees MiRXES operations in Singapore, USA, China, and Japan with a team of 300+ staff.

Prior to founding MiRXES in 2014, Lihan was a research scientist at the Bioprocessing Technology Institute, A*STAR where he co-developed a novel microRNA qPCR assay platform for microRNA biomarker and therapeutic target discovery. Lihan obtained his Ph.D. in Biochemistry from Yong Loo Lin School of Medicine, National University of Singapore. Lihan has authored more than 30 peer-reviewed publications and several patent applications.

Lihan was recognized by the MIT Technology Review as a member of the Innovators Under 35 (2015). He was also awarded the A*STAR Scientist-Entrepreneur Award in 2017, the NUS Outstanding Young Alumni Award, the EY Entrepreneur of The Year™ Singapore awards in 2021, and 2023 Singapore Business Award Young Business Leader of the Year. Under his leadership, MIRXES was named Singapore’s Most Promising Start-up in 2016 and Singapore’s Fastest Growing Companies in 2018, 2019 and 2020. MiRXES has successfully raised USD $180 million venture funding since 2016.